Please login to the form below
PNH
This page shows the latest PNH news and features for those working in and with pharma, biotech and healthcare.
Novartis’ Fabhalta approved by FDA as first oral monotherapy for rare blood disease PNH
Victor Bultó, president US, Novartis, described the approval as an "extraordinary moment” for the PNH community. ... This new, effective oral medicine may mean that patients can reset their expectations of living with PNH,” he said.
Latest news
-
Roche reports positive results for crovalimab as rare blood disease treatment
Roche has announced positive results from its phase 3 study of crovalimab in patients with paroxysmal nocturnal haemoglobinuria (PNH), a rare and life threatening blood condition. ... for PNH patients switching from currently approved C5 inhibitors to
-
Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study
PNH is a rare, chronic and life-threatening blood disease, affecting approximately ten to 20 people per million worldwide. ... part of the biology responsible for PNH while offering an oral monotherapy option.
-
Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study
with paroxysmal nocturnal haemoglobinuria (PNH) experiencing residual anaemia despite prior treatment with anti-C5s. ... part of the biology responsible for PNH while offering an oral monotherapy option.
-
Amgen announces positive results for Solaris biosimilar for paroxysmal nocturnal haemoglobinuria
PNH is a rare, acquired, life-threatening disease of the blood characterised by intravascular haemolytic anaemia, bone marrow failure and thromboembolic episodes, and is associated with a significant increase in mortality, ... with PNH in nearly 50
-
AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
PNH is a rare blood condition where red blood cells are destroyed and can result in blood clots and impaired bone marrow function. ... who are clinically stable after treatment with Alexion’s older PNH drug Soliris (eculizumab).
More from news
Approximately 4 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
It is a next- generation follow-on to Soliris, Alexion’s current PNH blockbuster – also a humanised monoclonal antibody – with more convenient dosing. ... Ultomiris received approval as an Orphan Drug from the FDA for adult patients with PNH in
-
Drug launches to watch in 2019
Alexion is bracing for the patent expiry of its blockbuster Soliris (eculizumab), used to treat paroxysmal nocturnal haemoglobinuria (PNH) and myasthenia gravis, which hit revenues of around $3bn in 2018. ... The follow-up, Ultomiris ALXN1210, is a second
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
